- Contact Us
- News and Events
- Investor Relations
- Locations and Facilities
- Careers
- About Our Site
- Accessibility Statement
- Privacy Policy
- Terms and Conditions
- For Employers and Medical Plan Providers
- For Pharmacists and Medical Professionals
- Drug Lists
- Drug Safety Alerts
- Emergency Response
- Mail Service Numbers, Forms and Information
- Specialty Pharmacy Services, Information and Forms
- Electronic Prior Authorization Information
- Clinical Drug Information
- Clinical Programs and Health Management
- Clinical Publications
- FAQs For Pharmacists and Pharmacy Staff
- Pharmacy Help Desk
- FAQs For Prescribers and Office Staff
- Contact Us | Health Professionals Only
Drug Safety Alerts
Potiga Discontinuation
7/05/2017
On July 5, 2017, GlaxoSmithKline announced their decision to discontinue Potiga® 50 mg, 200 mg, 300 mg and 400 mg tablets on June 30, 2017. This discontinuation is due to the limited usage of the medicine and not due to efficacy or safety reasons. As part of this discontinuation, GlaxoSmithKline issued a withdrawal of all lots of these products within expiry.
A complete list of the affected products is providedhere:
CVS Caremark Response: As a result of this issue, CVS Caremark will no longer be able to fill prescriptions for Potiga. Patients will need to obtain new prescriptions for a different medicine to treat their condition.
For more information about this issue, health care providers may contact GlaxoSmithKline at 1‑888-825-5249, Monday through Friday, 8:30 A.M through 5:30 P.M (ET) or visit us.gsk.com. You may also contact the U.S. Food and Drug Administration (FDA) consumer inquiry line at 1‑888-INFO-FDA (1-888-463-6332) or by accessing their Web site at www.fda.gov.